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Abstract
Introduction: Neuroendocrine tumors are a rare but diverse group of malignancies that arise in a wide range of
organ systems, including the mediastinum. Differential diagnosis includes other masses arising in the middle
mediastinum such as lymphoma, pericardial, bronchogenic and enteric cysts, metastatic tumors, xanthogranuloma,
systemic granuloma, diaphragmatic hernia, meningocele and paravertebral abscess.
Case presentation: We present a case of 42-year-old Caucasian man with a neuroendocrine tumor of the middle-
posterior mediastinum and liver metastases, which resembled a lymphoma on magnetic resonance imaging.
Conclusion: The differential diagnosis in patients with mediastinal masses and liver lesions should include
neuroendocrine tumor.
Introduction
Neuroendocrine tumors (NETs) are a rare but diverse
group of malignancies that arise in a wide range of
organ systems. This can therefore include the mediasti-
num [1,2].
Differential diagnosis includes other masses arising in
the middle and posterior mediastinum, such as lym-
phoma, pericardial, bronchogenic and enteric cysts,
metastatic tumors, xanthogranuloma, systemic granu-
loma, diaphragmatic hernia, meningocele and paraver-
tebral abscess. When a large mass is discovered,
pathological conditions of the anterior mediastinum,
such as thymoma, germ cell tumors, intrathoracic goiter,
lipoma, lymphangioma and aortic aneurysm, should also
be considered [3,4]. We present a case of a NET of the
middle-posterior mediastinum with liver metastases,
which resembled a lymphoma on magnetic resonance
imaging (MRI).
Case presentation
A 42-year-old Caucasian man was referred to our insti-
tution because of a recent onset of dysphonia. He had
no significant past medical history and his physical
examination was unremarkable. His erythrocyte
sedimentation rate was increased (38 mm/h; normal
range 0.00 to 17.00 mm/h). His blood cell count was
normal as were the results of his other laboratory tests,
including human immunodeficiency virus serology, urea
and electrolytes, liver function tests and lactate dehydro-
genase levels. Chorionic gonadotropin, neuron-specific
enolase (NSE), prostate specific antigen, carcinoembryo-
nic antigen, cancer antigen-125 and cancer antigen-19.9
were also tested and found to be negative. A noncon-
trast and postcontrast MRI of his mediastinum revealed
a 6 cm × 4 cm × 5 cm solid lesion in the left paratra-
cheal area, which appeared to enter and widen the aor-
topulmonary space. It also displaced his distal trachea
and branches of his left bronchus medially and infer-
iorly, respectively. On T2-weighted images, the mass
showed homogeneous high signal intensity. In contrast,
a low intensity signal was noted on T1-weighted images
and on the apparent diffusion coefficient (ADC) map
when diffusion weighted images (DWI) were considered
(Figure 1). The postcontrast T1-weighted images
showed poor enhancement within the solid lesion (Fig-
ure 2). No lymph node involvement was noted in other
areas of his chest. The MRI was then extended to his
abdomen and showed some solid lesions in the II, III
and VIII hepatic segments. These had the same patterns
of signal intensity observed in the mediastinal mass on
the T1- and T2-weighted images, before and after
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No vascular or biliary structures were invaded by the
hepatic mass and no abdominal lymph node involve-
ment was noted.
According to the radiological features, the diagnosis
was suspected lymphoma. Therefore, bioptical sampling
of the hepatic lesion was performed (Precisa: 18G × 2
cm). Microscopic examination revealed small sized cells,
some of them spindle-shaped, which were positive for
cytokeratins AE1/AE3, chromogranin, NSE and synapto-
physin on immunohistochemical analysis. Ten percent
of the cells expressed Ki67 and none of them showed a
CD3-CD20 pattern. According to the pathological
response, the diagnosis was a NET with hepatic
metastasis.
Systemic chemotherapy based on cisplatin plus etopo-
side was started and then replaced by a new scheme
based on capecitabine because of the progression of the
disease, which was particularly noticeable in his liver.
Therefore, a transarterial chemoembolization was con-
sidered as a suitable option to control the hepatic dis-
ease and then performed by emulsifying polyvinyl
alcohol particles and doxorubicin [5].
Discussion
N E T sa r ear a r eb u td i v e r s eg r o u po fm a l i g n a n c i e st h a t
arise in a wide range of organ systems. Gut-derived
NETs arise from the diffuse endocrine system and,
according to the 2002 World Health Organization clas-
sification system [6], are most simply classified based on
their site of origin as either ‘functional’ (symptomatic
hormone secretion) or ‘non-functional’ (no symptomatic
hormones). Many investigators still find it practical to
use the categorization of NETs based on the embryolo-
gic origin into foregut tumors (bronchi, stomach, pan-
creas, gallbladder, duodenum), midgut tumors (jejunum,
ileum, appendix, right colon), and hindgut tumors (left
colon, rectum). Although there has been continued
improvement in detection, NETs (most commonly, mid-
gut NETs) have frequently metastasized to the liver by
the time of diagnosis. A diverse range of imaging modal-
ities can be used for the assessment of NETs.
The case presented here was a suspected malignant
mediastinal tumor, because of the young age of our
patient and the presence of dysphonia. For this reason,
MRI was also extended to his abdomen. Radiological
features of low vascularization and the absence of
Figure 1 MRI of the patient’s mediastinum. (A) T2-weighted half Fourier acquisition dingle shot turbo spin echo (HASTE) sequence on axial
plane shows a mediastinal solid mass. (B,C) DWI at b1000 shows a homogeneous high signal intensity and a non-homogeneous low signal
intensity on ADC map (white arrows).
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by the hepatic and mediastinal lesions led to a first diag-
nostic hypothesis of mediastinal lymphoma with hepatic
spread. The latter hypothesis was also supported by the
fact that more than 80% of patients with Hodgkin’sd i s -
ease and almost 45% of patients with non-Hodgkin’s
lymphoma show intrathoracic involvement [7,8]. More-
over, in the thorax, lymphoma frequently involves the
anterior mediastinal and paratracheal regions [9]. How-
ever, due to the absence of systemic symptoms and the
presence of extrathoracic involvement at presentation,
which usually occurs in immunocompromised patients,
bioptical sampling of the hepatic lesions was performed
and revealed the presence of a neuroendocrine
malignancy.
A multimodality approach is optimal for detecting the
primary tumor and metastases and can include multide-
tector computed tomography (CT), functional imaging,
MRI, ultrasonography, endoscopy, digital subtraction
angiography and venous sampling.
For the evaluation of liver metastases, the use of tri-
ple-phase multidetector CT and contrast material-
enhanced MRI is suggested to establish a baseline,
which can help assess disease extent and allow post-
treatment comparison. The arterial anatomy of the liver
and portal vein patency can also be determined. Liver
metastases have low signal intensity on T1-weighted
MRI and high signal intensity on T2-weighted images
[10].
The treatment of patients with liver metastases is
complex, and there are often several factors that must
be taken into account. Curative surgery should always
be considered but is rarely possible due to the diffuse
nature of the disease.
NETs are relatively slow-growing tumors; therefore,
patients can survive for several years with current treat-
ment strategies. Interventional radiology has played an
increasingly important role.
Interventional radiologists could approach liver
metastases by performing procedures such as emboli-
zation, chemoembolization, targeted radionuclide ther-
apy and local ablative techniques (radiofrequency
ablation, cryotherapy and percutaneous ethanol injec-
tion) [11]. Radiological treatments may be combined
Figure 2 T1-weighted volumetric interpolated breath-hold examination (VIBE) sequences on axial planes. The post-contrast T1-weighted
images show poor enhancement within the solid lesion (white arrows).
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ered as a treatment option. Chemoembolization should
not be performed in patients in whom portal vein
obstruction, liver insufficiency, abscess, previous biliary
anastomoses and biliary obstruction have been discov-
ered during the diagnostic phase. Whether chemoem-
bolization should be used rather than embolization is
still a matter of debate, since recent evidence has
emerged that the addition of intraarterial chemother-
apy to embolization does not improve the outcome in
patients with carcinoid tumors [12]. Radionuclide ther-
apy could be proposed if other treatments are not pos-
sible or have failed; positive uptake of
111In-
pentetreotide has been proven on a previous scintigra-
phy and trained staff is available. Radionuclide therapy
should not be performed in cases of pregnancy and
lactation, or bone marrow dysfunction (hemoglobin
below 10 g/dL, white blood cell count fewer than 2 ×
10
3/mL, platelet count below 100/mL) [13]. Ablative
therapies should be performed as adjuncts to surgical
resection, for treatment of patients with unresectable
tumor, palliation and recurrence after surgical resec-
tion or prior ablation [14,15].
Conclusion
Mediastinal neuroendocrinet u m o r sa r eac h a l l e n g i n g
disease for clinicians and radiologists. Although the clin-
ical approach is still the mainstay both in the diagnostic
and therapeutic phases, the radiological approach could
provide valuable support. The differential diagnosis in
patients with mediastinal masses and liver lesions should
include neuroendocrine tumor.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
Figure 3 T2-weighted HASTE sequence on axial plane. Shows one of the solid liver lesions in the II segment, with the same patterns of
signal intensity showed by the mediastinal mass on the (A) T2-weighted and (B,C) T1-weighted images before contrast median injection (white
arrows).
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Page 4 of 6images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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